Clinical Trials Logo

Filter by:
NCT ID: NCT00796445 Terminated - Melanoma Clinical Trials

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Start date: December 1, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor. This Protocol Posting has been updated following Amendments 1 of the Protocol, March 2010. The impacted sections are outcome measures and entry criteria.

NCT ID: NCT00795639 Terminated - Clinical trials for Pulmonary Hypertension

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.

NCT ID: NCT00791700 Active, not recruiting - Clinical trials for Human Immunodeficiency Virus

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Start date: April 22, 2009
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents. This study will also determine whether maraviroc is safe to use in children and adolescents.

NCT ID: NCT00791479 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Start date: December 2008
Phase: Phase 2
Study type: Interventional

This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.

NCT ID: NCT00790036 Completed - Clinical trials for Diffuse Large B-cell Lymphoma

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

PILLAR2
Start date: July 2009
Phase: Phase 3
Study type: Interventional

Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy

NCT ID: NCT00787657 Completed - Clinical trials for Relapsing Remitting Multiple Sclerosis (RRMS)

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

BEACON
Start date: June 2008
Phase: N/A
Study type: Observational

- The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS). The Investigator will document the relevant medical data regarding multiple sclerosis at every hospital visit, the patient will fill in two questionnaires at every visit: one about coping with the disease and the other about anxiety and depression. - The Study particularly looks at the role of the support of the patient given by the multiple sclerosis nurses.The nurse will provide additional standardised information at start of treatment and will regularly phone the patient to ask standardised questions about the general condition with regard to the treatment, the disease and social support. At the end of the Study it will be assessed if the supportive measures and the standards in terms of adherence management in the hospital have some influence to increase long-term treatment adherence.

NCT ID: NCT00787202 Completed - Ulcerative Colitis Clinical Trials

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.

NCT ID: NCT00785928 Completed - Clinical trials for Rheumatoid Arthritis

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Start date: October 2008
Phase: Phase 2
Study type: Interventional

To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks

NCT ID: NCT00785785 Completed - Clinical trials for Gastrointestinal Stromal Tumor (GIST)

A Study of Nilotinib Versus Imatinib in GIST Patients

ENESTg1
Start date: March 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

NCT ID: NCT00785577 Completed - Clinical trials for Diabetic Neuropathy, Painful

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.